throbber
Ratain Curriculum Vitae – Revised 11/1/2016
`
`
`
`
`
`
`MARK J. RATAIN, M.D.
`
`November 23, 1954
`Washington, D.C.
`Married
`
`Harvard University, A.B. (biochemical sciences, magna cum laude)
`
`
`Date of Birth:
`Place of Birth:
`Marital Status:
`
`Education
`
`1976
`
`1980
`
`
`
`
`
`
`
`
`
`Yale University School of Medicine, M.D. (thesis -"Elicitation of the late nasal and
`cutaneous response: the possible role of eosinophils and basophils")
`
`
`Professional Positions
`
`1972-1977
`
`Computer programmer/systems analyst - part-time. System Sciences, Inc., Bethesda,
`MD
`
`Intern, Osler Medical Service, Johns Hopkins Hospital, Baltimore, MD
`
`Resident, Osler Medical Service, Johns Hopkins Hospital, Baltimore, MD
`
`Fellow, Section of Hematology/Oncology, Department of Medicine, The University of
`Chicago, Chicago, IL
`
`Associate Attending Member, Department of Medicine, Division of Hematology/Oncology,
`Michael Reese Hospital and Medical Center, Chicago, IL
`
`Instructor, Department of Medicine, Section of Hematology/Oncology, and Committee on
`Clinical Pharmacology, The University of Chicago, Chicago, IL
`
`Assistant Professor, Department of Medicine, Section of Hematology/Oncology, and
`Committee on Clinical Pharmacology, The University of Chicago, Chicago, IL
`
`Attending Member, Department of Medicine, Division of Hematology/Oncology, Michael
`Reese Hospital and Medical Center, Chicago, IL
`
`Director of Clinical Pharmacology, Section of Hematology/Oncology, The University of
`Chicago, Chicago, IL
`
`Director, Developmental Therapeutics Program, Cancer Research Center, The University
`of Chicago, Chicago, IL
`
`Associate Professor, Department of Medicine, Section of Hematology/Oncology,
`Committee on Clinical Pharmacology, and Cancer Research Center, The University of
`Chicago, Chicago, IL
`
`Chairman, Committee on Clinical Pharmacology and Pharmacogenomics*, The University
`of Chicago, Chicago, IL
`
`Professor, Department of Medicine, Section of Hematology/Oncology, Committee on
`Clinical Pharmacology and Pharmacogenomics*, and Cancer Research Center, The
`University of Chicago, Chicago, IL
`
`1
`
`
`1980-1981
`
`1981-1983
`
`1983-1986
`
`
`1986-1988
`
`
`1986-1987
`
`
`1987-1991
`
`
`1988-1989
`
`
`1988-1992
`
`
`1991-1995
`
`
`1991-1995
`
`
`1992-2010
`
`
`1995-2002
`
`
`
`
`
`
`
`Ex. 1064-0001
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`1995-2000
`
`Co-Director, Clinical and Experimental Therapeutics Program, Cancer Research Center,
`The University of Chicago, Chicago, IL
`
`Leon O. Jacobson Professor, Department of Medicine, Section of
`Hematology/Oncology, Committee on Clinical Pharmacology and
`Pharmacogenomics*, and Comprehensive Cancer Centert, The University of
`Chicago, Chicago, IL
`Associate Director for Clinical Sciences, Comprehensive Cancer Centert, The
`University of Chicago, Chicago, IL
`
`Director, Center for Personalized Therapeutics, The University of Chicago,
`Chicago, IL
`
`Chief Hospital Pharmacologist, The University of Chicago Medicine&, Chicago, IL
`
`
`2002-
`
`
`
`
`1999-
`
`
`2010-
`
`
`
`
`2010-
`
`*previously Committee on Clinical Pharmacology
`tpreviously Cancer Research Center
`&previously University of Chicago Medical Center
`
`
`
`2
`
`Ex. 1064-0002
`
`

`
`
`
`
`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`Research Review and Related Federal Service
`
`National Institutes of Health
`Ad Hoc Reviewer, Experimental Therapeutics Study Section, Division of Research Grants 1986
`Special Review Committee, National Cancer Institute 1991
`Consultant Reviewer, Department of Veteran Affairs 1993
`Ad Hoc Reviewer, National Cancer Institute 1993
`Special Study Section (Small Business Innovative Research Program), Division of Research
`Grants 1994
`
`
`Ad Hoc Reviewer, National Center for Research Resources 1997
`Reviewer, Intramural Review Office, Pediatric Oncology Branch, National Cancer Institute 1998
`Clinical Oncology Special Emphasis Panel, Oncological Science Initial Review Group, Center for
`Scientific Review 1999-2000
`Clinical Advisory Working Group, National Institute of General Medical Sciences 1999
`Ad Hoc Reviewer, Drug Development Group, National Cancer Institute 2000, 2001
`Data and Safety Monitoring Board (T-Cell Depleted Auto Stem Cell Transplant Trial for Systemic
`Sclerosis), National Institute of Arthritis and Musculoskeletal Diseases 2002-2005
`Clinical Trials Working Group, National Cancer Advisory Board, National Cancer Institute 2004-
`2005
`Investigational Drug Steering Committee, National Cancer Institute 2005-2016 (Co-Chair, Steering
`Committee, 2005-2008; Co-Chair, Clinical Trials Design Task Force, 2012-2016)
`National Institute of General Medical Sciences Special Emphasis Panel 2006
`Subcommittee J - Population and Patient-Oriented Training, National Cancer Institute Initial
`Review Group (Ad Hoc Reviewer 2006; Member 2006-2009)
`Reviewer, NIH Director’s New Innovator Awards 2008
`Reviewer, Center for Scientific Review 2010
`National Institute of General Medical Sciences Special Emphasis Panel 2013, 2014
`
`
`Dutch Cancer Society
`
`Ad Hoc Reviewer 1994, 1999
`
`The Cancer Society of New Zealand
`
`Ad Hoc Reviewer 1994
`
`Joint Infrastructure Fund, Wellcome Trust
`Ad Hoc Reviewer 1998, 2000
`
`
`Institut National du Cancer
`
`Ad Hoc Reviewer 2010
`
`Christian Doppler Research Association
`
`Ad Hoc Reviewer 2011
`
`Pennsylvania Department of Health
`
`Ad Hoc Reviewer 2012-2014, 2016
`
`Florida Department of Health
`
`Ad Hoc Reviewer 2015-2016
`
`
`
`
`3
`
`Ex. 1064-0003
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`National and International Organizations
`
`Cancer and Leukemia Group B
`Chemotherapy Committee 1988-1990
`Breast Committee 1989-1998
`
`Ad Hoc Committee on Relations with Pharmaceutical Companies 1989-1990
`Pharmacology and Experimental Therapeutics Committee 1990-2011 (Chair, 1994-2011)
`Ad Hoc Nominating Committee 1989-1990
`
`Industrial Relations Committee 1992-1993
`
`Executive Committee 1993-1996
`
`Board of Directors 1993-2011
`
`
`Chair, Ad Hoc Committee on Conflict of Interest 1994-1996
`Chair, Conflict of Interest Committee 1996-1998
`
`
`
`
`
`
`
`
`
`
`
`
`American Federation for Clinical Research
`
`Medical School Representative 1988-1989
`
`American Society for Clinical Pharmacology and Therapeutics
`Hematologic and Neoplastic Diseases Section 1988-2007 (Vice Chair, 1988-1992; Chair, 1992-
`1995)
`Government Affairs Committee 1990-2002 (Vice Chair, 1997-2002)
`Long Range Planning Committee 1990-1993
`Committee on Coordination of Scientific Sections 1992-1995, 1998-2001 (Chair, 1998-2001)
`Scientific Program Committee 1993-1994, 1996-1998, 2001-2004 (Vice Chair 2001-2002, Chair
`2002-2003, Immediate Past Chair 2003-2004)
`Nominating Committee 1995-1996
`Board of Directors 1997-2001
`Executive Committee 1998-2001
`Communications and Public Relations Committee 1998-2001
`Committee on Substance Abuse 1998-2001
`Membership Committee 2000-2003
`Molecular Pharmacology and Pharmacogenetics Section 2001-
`Pharmacokinetics and Drug Metabolism Section 2001-2007
`Oncology Section 2007-
`Pharmacometrics and Pharmacokinetics 2007-
`
`
`
`
`International Workshops on Pharmacodynamics of Anticancer Agents
`First International Workshop on Pharmacodynamics of Anticancer Agents (Fontana, WI), Co-
`Organizer 1989
`Second International Workshop on Pharmacodynamics of Anticancer Agents (Eze, France), Co-
`Organizer 1992
`Third International Workshop on Pharmacodynamics of Anticancer Agents (Irvington, VA), Co-
`Organizer 1995
`Fourth International Workshop on Pharmacodynamics of Anticancer Agents (Dunkeld, Scotland),
`Co-Organizer 1998
`Fifth International Workshop on Pharmacodynamics of Anticancer Agents (Sea Island, GA), Co-
`Organizer 2001
`Sixth International Workshop on Pharmacodynamics of Anticancer Agents (Venice, Italy), Co-
`Organizer 2004
`Seventh International Workshop on Pharmacodynamics of Anticancer Agents (Guanacaste,
`Costa Rica), Co-Organizer 2007
`Eighth International Workshop on Pharmacodynamics of Anticancer Agents (Hakone, Japan), Co-
`Organizer 2010
`Ninth International Workshop on Pharmacodynamics of Anticancer Agents (Hexham, England),
`Co-Organizer 2013
`Tenth International Workshop on Pharmacodynamics of Anticancer Agents (Skamania, WA), Co-
`Organizer 2016
`
`
`
`4
`
`Ex. 1064-0004
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`American Society of Clinical Oncology
`Committee for Patient Advocacy 1990-1992
`Audit and Finance Committee 1990-1994 (Chair, 1990-1994)
`Secretary-Treasurer 1994-1997
`Board of Directors 1994-1997
`Executive Committee 1994-1997
`Strategic Planning Committee 1994-1998
`Program Committee 1995-1997, 1998-2000 (Subchair for Clinical Pharmacology, 1995-1996;
`Board Liaison, 1995-1996)
`Industry/Exhibits Committee 1995-1997 (Board Liaison, 1995-1997)
`Ad Hoc Committee to Develop ASCO OnLine 1995
`Clinical Methods Workshop Program Committee 1995-1997
`OnLine Committee 1995-2000
`Subcommittee on Phase I Clinical Trials, Public Issues Committee 1996 (Chair, 1996)
`Publications Committee 1997-2000 (OnLine Committee Liaison 1997-2000)
`Continuing Medical Education Committee 1997-2000 (Chair, 1997-1999; Immediate Past Chair,
`1999-2000)
`Cancer Education Committee 2000-2003 (Track Team Leader, Pharmacology/Drug Development,
`2002-2003)
`Translational Research Task Force 2005
`Cancer Research Committee 2007-2010 (Chair, Pre-Phase III Working Group 2008-2010)
`
`European Organization for Research and Treatment of Cancer
`
`Pharmacology and Molecular Mechanisms Group (Corresponding Member) 1990-2004
`
`National Board of Medical Examiners
`Step 3 Test Material Development Committee for Utilization of Resources, United States Medical
`Licensing Examination 1997-1998
`
`
`Pharmacogenomics (previously Pharmacogenetics) of Anticancer Agents Research Group
`
`Founding Chair 2000-2015
`
`Pharmacogenomics (previously Pharmacogenetics) Research Network
`Steering Committee 2000-2015 (Chair, 2000-2003)
`Coordinating Committee 2003-2004, 2007-2008
`Cancer Partnerships Working Group 2006-2010 (Co-Chair, 2006-2010)
`
`
`
`
`U.S. Pharmacopeia
`Oncologic Disease Expert Committee 2000-2003
`
`
`Institut Pasteur Euroconferences
`Pharmacogenomics 2, Scientific Committee 2001-2002
`
`American Board of Clinical Pharmacology
`Governing Board 2002-2007
`Credentials Committee 2002-2007 (Chair, 2004-2007)
`
`
`
`American Association for Cancer Research
`Program Committee 2002-2003, 2006-2007, 2012-2013, 2014-2016
`Scientific Committee AACR-EORTC-NCI Symposia 2003-2006
`Education Committee 2006-2007
`Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant Scientific Review
`Committee 2012-2015
`
`
`Accreditation Council for Continuing Medical Education
`Content Validation Advisory Group 2003
`
`
`
`
`
`5
`
`Ex. 1064-0005
`
`

`
`
`
`
`
`
`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`
`Sapporo Cancer Seminar Foundation
`25th International Symposium, Organizing Committee 2005
`
`
`Japanese Foundation for Cancer Research
`
`International Symposia, Member 2007-2014
`
`The ASCO Foundation
`
`Translational Research Professorship Review Subcommittee 2007-2008
`
`Alliance for Clinical Trials in Oncology
`Pharmacogenomics and Population Pharmacology Committee 2011- (Chair, 2011- )
`
`
`International Workshops on Dose Optimization Strategies for Targeted Drugs
`1st International Workshop on Dose Optimization Strategies for Targeted Drugs: Focus on
`Oncolytics (Zaandam, Netherlands), Co-Chair 2015
`
`
`
`
`
`6
`
`Ex. 1064-0006
`
`

`
`
`
`
`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`Institutional Committees
`
`Michael Reese Hospital and Medical Center
`
`Intern Selection Committee, Department of Medicine 1987-1988
`
`Institutional Review Board, Alternate 1988-1989
`
`Pharmacy, Therapeutics and Antibiotic Committee 1988-1989
`
`The University of Chicago
`
`Chairman, Office of Research Services Faculty Advisory Committee, Biological Sciences Division
`1992-1995
`Executive Committee, Cancer Research Center 1992-2004
`Divisional Executive Committee, Biological Sciences Division 1992-2009
`Clinical Chairmen's Committee, Biological Sciences Division 1992-2007
`American Cancer Society Institutional Research Grant Committee, Cancer Research Center
`1994-1998
` Clinical Trials Director Search Committee, Department of Health Studies 1997-1998
`
`Co-Chair, Pharmacoepidemiology Search Committee 1998-1999
`
`Chair, Entrepreneurs Committee, Department of Medicine 1999-2000
`Radiology Search Committee, Biological Sciences Division 2000-2001
`Committee on Appointments and Promotions, Biological Sciences Division 2000-2004
`Chair, Clinical Research Working Group, Department of Medicine 2000-2001
`Protocol Accrual Closure and Monitoring Committee, Cancer Research Center 2000-2001
`Committee on Intellectual Property 2001-2004
`Population Sciences Search Committee, Cancer Research Center 2001
`Human Genetics Search Committee, Biological Sciences Division 2002-2003
`Cancer Advisory Committee, Comprehensive Cancer Centert 2004-
`Clinical Research Oversight Committee, Cancer Research Center 2004- (Chair 2004-2007)
`Cardiology Search Committee, Department of Medicine 2005-2006
`Entrepreneurial and Translational Science Advisory Committee, Department of Medicine 2006-
`2007
`Clinical Research Advisory Committee, Comprehensive Cancer Centert 2007- (Chair 2007- )
`Executive Committee, Comprehensive Cancer Centert 2008-
`UChicago Tech Faculty Advisory Committee, 2008-2010
`Chicago Innovation Initiative Working Group, 2012-2013
`Research Strategy Advisory Committee, Department of Medicine 2016-
`
`The University of Chicago Medicine
`Risk Management and Patient Safety Executive Committee, 2013-
`
`
`
`
`
`7
`
`Ex. 1064-0007
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`Service to Other Institutions
`
`Georgetown University
`External Scientific Advisory Committee, Lombardi Cancer Center 2002-2011
`
`St. Jude Children’s Research Hospital
`External Advisory Board, Cancer Center 2005-
`
`The First People’s Hospital Affiliated Shanghai Jiangtong University
`External Scientific Advisor in Pharmacogenetics, The Shanghai Transplantation Research Center
`2008
`
`
`Thomas Jefferson University
`External Scientific Advisory Committee, Kimmel Cancer Center 2009-2013
`
`Radboud University
` Scientific Advisory Board, EuroTARGET 2011-2016
`
`Dartmouth University
`External Scientific Advisory Board, Norris Cotton Cancer Center 2013-
`
`University of Texas Southwestern
`External Advisory Board, Kidney SPORE 2014-
`
`
`U-PGx Consortium
` Scientific Advisory Board 2016-
`
`National University Cancer Centre Singapore
` Scientific Advisory Board 2016-
`
`
`Regional Committees
`
`1987-1992
`1987-1992
`1989-1992
`1990-1991
`
`
`
`
`
`Certification
`
`1981
`1983
`1983
`1985
`1986
`1993
`2014-
`
`
`
`
`
`
`
`
`
`
`
`
`
`New Agents Committee, Illinois Cancer Council
`Biological Response Modifiers Committee, Illinois Cancer Council
`Chemoprevention Committee, Illinois Cancer Council
`Illinois Division Research Committee, American Cancer Society
`
`
`Diplomate, National Board of Medical Examiners
`Licensed Physician and Surgeon, State of Illinois
`Diplomate, American Board of Internal Medicine
`Diplomate, Medical Oncology, American Board of Internal Medicine
`Diplomate, Hematology, American Board of Internal Medicine
`Diplomate, American Board of Clinical Pharmacology
`Maintenance of Certification, Internal Medicine, Medical Oncology, and
`Hematology, American Board of Internal Medicine
`
`8
`
`Ex. 1064-0008
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`Professional Membership
`
`1983-
`1986-
`1986-
`1987-
`1988-
`1988-
`1990-
`1992-
`2007-
`2011-
`
`American College of Physicians (Fellow, 1990)
`American Society of Clinical Oncology (Fellow, 2007)
`American Federation for Clinical Research
`American Society for Clinical Pharmacology and Therapeutics
`American Association for Cancer Research
`American Society of Hematology
`Central Society for Clinical Research
`European Society for Medical Oncology
`Association of American Physicians
`American College of Clinical Pharmacology (Honorary Fellow, 2011)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`9
`
`Ex. 1064-0009
`
`

`
`
`
`
`
`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`Honors and Awards
`
`1975
`1985
`1993
`1994-
`1997-
`1999
`1999-
`2001
`2002-
`2002-
`2004
`
`Dreyfus Fellowship, Harvard University, Department of Biochemistry
`Central Society for Clinical Research, Trainee Award
`Unit Award, Pharmaceutical Research and Manufacturers of America Foundation
`Listed in The Best Doctors in America (Woodward/White)
`Listed in Chicago’s Top Doctors, Chicago
`Honorary Visiting Expert, Ministry of Health, Singapore
`Listed in America’s Top Doctors (Castle Connolly)
` Distinguished Lecturer, Cancer Institute of New Jersey
`
`Listed in Top Doctors: Chicago Metro Area (Castle Connolly)
`
`Leon O. Jacobson Professorship, The University of Chicago
`
`Top Membership Recruiter, American Society for Clinical Pharmacology and
`Therapeutics
`Listed in America’s Top Doctors for Cancer (Castle Connolly)
`Special Recognition Award, National Cancer Institute
`Chair, 60th Annual Senior Scientific Session, The University of Chicago
`Elected to Association of American Physicians
`Statesman Award, American Society of Clinical Oncology
`Emil J. Freireich Award for Clinical Research, MD Anderson Cancer Center
`Institute for Pharmacogenomics and Individualized Therapy Clinical Service Award, The
`University of North Carolina at Chapel Hill
`Director’s Service Award, National Cancer Institute
`Research Achievement Award in Clinical Pharmacology and Translational Research,
`American Association of Pharmaceutical Scientists
`Rawls-Palmer Progress in Medicine Award, American Society for Clinical Pharmacology
`and Therapeutics
`Henry T. Lynch Lectureship in Medical Genetics, NorthShore University Health System
`Robert Hart Waldman, M.D., Lecture, The University of Nebraska Medical Center
`Translational Research Professorship, American Society of Clinical Oncology
`Certificate of Appreciation, Japanese Society of Medical Oncology
`Honorary Fellow, American College of Clinical Pharmacology
`Visiting Professor, Food and Drug Administration, Center for Drug Evaluation and
`Research, Office of Clinical Pharmacology
`Special Recognition, Department of Pharmaceutics and Pharmaceutical Chemistry,
`College of Pharmacy, University of Utah
`Spotlight on Science Featured Speaker, American Society of Health System Pharmacists
`Keynote Speaker, University of Illinois College of Medicine Research Symposium
`Keynote Speaker, Hospital Pharmacy Europe Live
`Keynote Speaker, Emory University Phase I Unit Five Year Celebration
`Award in Excellence in Clinical Pharmacology, Pharmaceutical Research and
`Manufacturers of America Foundation
`Nominee (Scientific Advances), Giants of Cancer Care, OncLive
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2005-
`2005
`2006
`2007
`2007
`2008
`2008
`
`2009
`2009
`
`2010
`
`2010
`2011
`2011
`2011
`2011
`2012
`
`2012
`
`2013
`2014
`2014
`2014
`2015
`
`2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`10
`
`Ex. 1064-0010
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`Significant Editorial Responsibilities
`
`1990-2003
`1994-1996
`1995-
`
`1996-2002
`1999-2001
`1999
`2001-2007
`2001-2004
`2001-2008
`2003-
`
`2003-2009
`2005-
`
`2012-
`
`
`Patents
`
`1998
`
`
`
`2002
`
`2002
`
`2004
`
`2008
`
`2010
`
`2014
`
`
`
`
`
`
`
`
`
`
`
`
`
`Cancer Chemotherapy and Pharmacology, Editorial Board
`Clinical Cancer Research, Editorial Board
`Investigational New Drugs, Editorial Advisory Board
`Clinical Cancer Research, Associate Editor
`Clinical Pharmacology and Therapeutics, Editorial Advisory Committee
`Classic Papers and Current Comments: Clinical Pharmacology, Guest Editor
`Journal of Clinical Oncology, Associate Editor
`Current Pharmacogenomics, Editor-in-Chief
`Clinical Pharmacology and Therapeutics, Editorial Board
`Clinical Advances in Hematology & Oncology, Section Editor in Oncology
`Clinical Cancer Research, Editorial Board
`Pharmacogenetics and Genomics, Co-Editor-in-Chief
`Clinical Cancer Research, Editorial Board
`
`Camptothecin drug combinations and methods with reduced side effects (inventors Mark
`J. Ratain & Elora Gupta), United States Patent No.: 5,786,344 (7/28/1998)
`Methods for detection of promoter polymorphism in a UGT gene promoter (inventors
`Anna Di Rienzo, Lalitha Iyer & Mark J. Ratain), United States Patent No.: 6,395,481
`(5/28/2002)
`Methods for detection of promoter polymorphism in a UGT gene promoter (inventors
`Anna Di Rienzo, Lalitha Iyer & Mark J. Ratain), United States Patent No.: 6,472,157
`(10/29/2002)
`Campothecin drug combination and methods with reduced side effects (inventors Mark J.
`Ratain & Elora Gupta), European Patent No.: 0768895 (9/22/2004)
`Methods and compositions for predicting irinotecan toxicity (inventors Mark J. Ratain,
`Federico Innocenti, Anna Di Rienzo & Carrie Grimsley), European Patent No.: 1629111
`(5/28/2008)
`Methods for predicting irinotecan toxicity (inventors Mark J. Ratain, Federico Innocenti,
`Anna Di Rienzo & Carrie Grimsley), United States Patent No.: 7,807,350 (10/5/2010)
`Method for identification of sensitivity of a patient to telomerase inhibition therapy
`(inventors Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio
`Benedetti), United States Patent No.: 8,877,723 (11/4/2014)
`
`
`Mailing Address:
`
`Mark J. Ratain, M.D.
`The University of Chicago Medicine
`MC2115
`5841 S. Maryland Avenue
`Chicago, Illinois 60637
`Email: mratain@medicine.bsd.uchicago.edu or mjr1@uchicago.edu
`Telephone: (773) 702-4400
`Fax: (773) 702-3969
`
`
`
`11
`
`Ex. 1064-0011
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`Original Research Articles
`
`1.
`
`Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K. Treatment of hairy cell
`leukemia with recombinant alpha-2-interferon. Blood 65, 644-648 (1985).
`Bardawil RG, Groves C, Ratain MJ, Golomb HM, Vardiman JW. Changes in peripheral blood and
`bone marrow specimens following therapy with recombinant alpha2 interferon for hairy cell
`leukemia. Am J Clin Path 85, 194-201 (1986).
`Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Vardiman
`J, Burke J, Brady J, Bonnem E, Spiegel R. Alpha-2 interferon therapy of hairy cell leukemia: A
`multicenter study of 64 patients. J Clin Oncol 4, 900-905 (1986).
`Schilsky RL, O'Laughlin K, Ratain MJ. Phase I clinical and pharmacological study of thymidine
`(NSC 21548) and cis-diamminedichloroplatinum (II) in patients with advanced cancer. Cancer
`Res 46, 4184-4188 (1986).
`Ratain MJ, Vogelzang NJ. Phase I and pharmacological study of vinblastine by prolonged
`continuous infusion. Cancer Res 46, 4827-4830 (1986).
`Bennett CL, Vogelzang NJ, Ratain MJ, Reich S. Hyponatremia and other toxic effects during a
`phase I trial of recombinant human gamma interferon and vinblastine. Cancer Treat Rep 70,
`1081-1084 (1986).
`Ratain MJ, Vogelzang NJ, Sinkule JA. Interpatient and intrapatient variability in vinblastine
`pharmacokinetics. Clin Pharmacol Ther 41, 61-67 (1987).
`Ratain MJ, Golomb HM, Bardawil RG, Vardiman JW, Westbrook CA, Kaminer LS, Lembersky
`BC, Bitter MA, Daly K. Durability of responses to interferon alfa-2b in advanced hairy cell
`leukemia. Blood 69, 872-877 (1987).
`Vokes EE, Bitter MA, Ratain MJ, Prystowsky MB, Daly K, Golomb HM. Flow cytometry in hairy
`cell leukemia before and during interferon alfa-2b therapy. Cancer 59, 1987-1991 (1987).
`Ratain MJ, Vogelzang NJ. Limited sampling model for vinblastine pharmacokinetics. Cancer
`Treat Rep 71, 935-939 (1987).
`Ratain MJ, Kaminer LS, Bitran JD, Larson RA, LeBeau MM, Skosey C, Purl S, Hoffman PC,
`Wade J, Vardiman JW, Daly K, Rowley JD, Golomb HM. Acute nonlymphocytic leukemia
`following etoposide and cisplatin combination chemotherapy for advanced non-small cell
`carcinoma of the lung. Blood 70, 1412-1417 (1987).
`Vogelzang NJ, Ruane M, Ratain MJ, Dhowlatshahi K, Chodak GW. A programmable and
`implantable pumping system for systemic chemotherapy: A performance analysis in 52 patients.
`J Clin Oncol 5, 1968-1976 (1987).
`Lembersky BC, Ratain MJ, Westbrook C, Golomb HM. Rapid response to 2'deoxycoformycin in
`advanced hairy cell leukemia after failure of interferons alpha and gamma. Amer J Hematol 27,
`60-62 (1988).
`Golomb HM, Ratain MJ, Fefer A, Thompson J, Golde DW, Ozer H, Portlock C, Silber R,
`Rappeport J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW. Randomized study of
`the duration of treatment with interferon alfa-2b in patients with hairy cell leukemia. J Natl Cancer
`Inst 80, 369-373 (1988).
`Vardiman JW, Gilewski TA, Ratain MJ, Bitter MA, Bradlow BA, Golomb HM. Evaluation of Leu M-
`5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique.
`Am J Clin Path 90, 250-256 (1988).
`Lembersky BC, Ratain MJ, Golomb HM. Skeletal complications in hairy cell leukemia: diagnosis
`and therapy. J Clin Oncol 6, 1280-1284 (1988).
`Ratain MJ, Staubus AE, Schilsky RL, Malspeis L. Limited sampling models for amonafide (NSC
`308847) pharmacokinetics. Cancer Res 48, 4127-4130 (1988).
`12
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`10.
`
`11.
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`17.
`
`
`
`Ex. 1064-0012
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`18.
`
`19.
`
`20.
`
`21.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`28.
`
`29.
`
`30.
`
`31.
`
`32.
`
`33.
`
`34.
`
`
`
`Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA, Bitran JD. Human plasma
`pharmacokinetics of thiotepa following administration of high-dose thiotepa and
`cyclophosphamide. J Clin Oncol 6, 1192-1196 (1988).
`Ratain MJ, Vardiman JW, Barker CM, Golomb HM. Prognostic variables in hairy cell leukemia
`after splenectomy as initial therapy. Cancer 62, 2420-2424 (1988).
`Ratain MJ, Golomb HM, Vardiman JW, Westbrook CA, Barker C, Hooberman A, Bitter MA, Daly
`K. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: Analysis of prognostic
`variables. J Clin Oncol 6, 1714-1721 (1988).
`Ratain MJ, Schilsky RL, Wojack BR, Simon T, Senekjian E, Vogelzang NJ. Hydroxyurea and
`etoposide: In vitro synergy and phase I clinical trial. J Natl Cancer Inst 80, 1412-1416 (1988).
`Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA. Pharmacokinetics and
`pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther 45, 340-
`347 (1989).
`Vokes EE, Schilsky RL, Choi KE, Magid DM, Guarnieri CM, Whaling SM, Ratain MJ,
`Weichselbaum RR, Panje WR. A randomized study of inpatient versus outpatient continuous
`infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer 63, 30-
`36 (1989).
`Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E, Liebner
`MA. Adaptive control of etoposide dosing: Impact of interpatient pharmacodynamic variability.
`Clin Pharmacol Ther 45, 226-233 (1989).
`Choi KE, Ratain MJ, Williams SF, Golick JA, Beschorner JC, Fullem L, Bitran JD. Plasma
`pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy
`and autologous bone marrow reinfusion. Cancer Res 49, 1318-1321 (1989).
`Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA. A limited sampling
`strategy for cyclophosphamide pharmacokinetics. Cancer Res 49, 3129-3133 (1989).
`Moormeier J, Ratain MJ, Vardiman JW, Daly K, Golomb HM. Low dose interferon in hairy cell
`leukemia. J Natl Cancer Inst 81, 1172-1174 (1989).
`Moormeier J, Westbrook CA, Ratain MJ, Golomb HM. Interferon alfa-2B antibodies and clinical
`resistance in a patient with hairy cell leukemia. Leukemia Lymphoma 1, 43-45 (1989).
`Johnston C, Senekjian EK, Ratain MJ, Talerman A. Conservative management of primary
`cervical lymphoma using combination chemotherapy: a case report. Gynecol Oncol 35, 391-394
`(1989).
`Schilsky RL, Ratain MJ. Clinical pharmacokinetics of high dose leucovorin after intravenous and
`oral administration. J Natl Cancer Inst 82, 1411-1415 (1990).
`Richards JM, Mick R, Latta JM, Daly K, Ratain MJ, Vardiman JW, Golomb HM. Serum soluble IL-
`2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood
`76, 1941-1945 (1990).
`Ratain MJ, Robert J, van der Vijgh WJF. Limited sampling models for doxorubicin
`pharmacokinetics. J Clin Oncol 9, 871-876 (1991).
`Vokes EE, Ratain MJ, Janisch L, Hoffman PC, Golomb HM, Schilsky RL. A phase I study of
`cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy
`naive patients. Eur J Cancer 27, 217-218 (1991).
`Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ,
`Thompson J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW. Survival experience of
`195 patients with hairy cell leukemia treated in a multi-institutional study with interferon-alfa 2b.
`Leukemia Lymphoma 4, 99-102 (1991).
`
`13
`
`Ex. 1064-0013
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`35.
`
`Vokes EE, Raschko JW, Vogelzang NJ, Warfield EE, Ratain MJ, Doroshow JH, Schilsky RL. Five
`day infusion fluorodeoxyuridine with high dose oral leucovorin: A phase I study. Cancer
`Chemother Pharmacol 28, 69-73 (1991).
`Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically-based dosing of
`etoposide: A means of safely increasing dose-intensity. J Clin Oncol 9, 1480-1486 (1991).
`Golomb HM, Ratain MJ, Fefer A, Thompson J, Portlock CS, Ozer H, Mick R, Chiavello J, Israel
`RJ, Bonnem EM. Low dose interferon alfa-2B for the induction of remission of hairy cell leukemia:
`A multi-institutional study of 49 patients. Leukemia Lymphoma 5, 335-340 (1991).
`Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ, Ratain MJ. Treatment
`of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J
`Clin Oncol 9, 2021-2026 (1991).
`Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Paradoxical
`relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 50, 573-
`579 (1991).
`Mick R, Ratain MJ. Modeling interpatient pharmacodynamic variability of etoposide. J Natl
`Cancer Inst 83, 1560-1564 (1991).
`Vokes EE, Moormeier JA, Ratain MJ, Egorin MJ, Haraf DJ, Mick R, Weichselbaum RR. 5-
`fluorouracil, hydroxyurea, and escalating doses of continuous infusion cisplatin with concomitant
`radiotherapy: A clinical and pharmacologic study. Cancer Chemother Pharmacol 29, 178-184
`(1992).
`Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, Jones RJ. A phase I/II
`trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 84, 98-
`103 (1992).
`Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M. Ethical issues in phase I oncology
`research: A comparison of investigators and IRB chairpersons. J Clin Oncol 10, 1810-1816
`(1992).
`Golomb HM, Ratain MJ, Mick R, Daly K. Interferon treatment for hairy cell leukemia; an update
`on a cohort of 69 patients treated from 1983-86. Leukemia 6,1177-1180 (1992).
`Schilsky RL, Ratain MJ, Janisch L, Vogelzang NJ, Lucas VS, Ravitch J, Hohneker JA,
`Clendeninn NJ, Tuttle RL. Phase I clinical and pharmacologic study of 502U83 administered as a
`24 hour continuous intravenous infusion. Cancer Chemother Pharmacol 31, 283-288 (1993).
`Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Hamasaki V, Kozloff M, Weichselbaum RR,
`Panje WR, Wenig B, Berezin F. Cisplatin, 5-fluorouracil and leucovorin augmented by interferon
`alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 11, 360-368
`(1993).
`Mick R, Ratain MJ. Model-guided determination of maximal tolerated dose in phase I clinical
`trials: Evidence for increased precision. J Natl Cancer Inst 85, 217-223 (1993).
`Ratain MJ, Priest E, Janisch L, Vogelzang NJ. Phase I study of subcutaneous recombinant
`interleukin-2 and interferon alfa-2a. Cancer 71, 2371-2376 (1993).
`Schilsky RL, Janisch L, Berezin F, Mick R, Vogelzang NJ, Ratain MJ. Phase I clinical and
`pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
`Cancer Res 53, 1293-1296 (1993).
`Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Phase I study of
`amonafide dosing based on acetylator phenotype. Cancer Res 53, 2304-2308 (1993).
`
`36.
`
`37.
`
`38.
`
`39.
`
`40.
`
`41.
`
`42.
`
`43.
`
`44.
`
`45.
`
`46.
`
`47.
`
`48.
`
`49.
`
`50.
`
`
`
`
`
`14
`
`Ex. 1064-0014
`
`

`
`Ratain Curriculum Vitae – Revised 11/1/2016
`
`51.
`
`52.
`
`53.
`
`54.
`
`55.
`
`56.
`
`57.
`
`58.
`
`59.
`
`60.
`
`61.
`
`62.
`
`63.
`
`64.
`
`65.
`
`66.
`
`
`
`Vokes EE, Dolan ME, Krishnasamy

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket